Quick Answer
iSpecimen Inc. reported Total Revenue of $9.29 million for fiscal year 2024.
iSpecimen Inc. — Key Financials by Year
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Total Revenue | $9.29M -6.4% |
$9.93M -4.6% |
$10.40M -6.6% |
$11.14M +36.1% |
$8.18M | — |
| Revenue (ASC 606) | — | $9.93M -4.6% |
$10.40M -6.6% |
$11.14M +36.1% |
$8.18M | — |
| Net Income | -$12.50M -12.6% |
-$11.10M -8.3% |
-$10.25M -14.3% |
-$8.96M -92.6% |
-$4.65M | — |
| Diluted EPS | -$17.58 +28.4% |
-$24.55 -2016.4% |
-$1.16 +44.5% |
-$2.09 +57.9% |
-$4.97 | — |
| Total Assets | $9.35M -40.9% |
$15.82M -35.7% |
$24.62M -31.1% |
$35.72M +475.2% |
$6.21M | — |
| Cash and Equivalents | $1.88M -19.9% |
$2.34M -84.7% |
$15.31M -44.8% |
$27.74M +3886.0% |
$695.9K | — |
| Stockholders Equity | $3.31M -66.0% |
$9.74M -52.0% |
$20.31M -31.8% |
$29.79M +209.2% |
-$27.28M -20.1% |
-$22.72M |
| Operating Income | -$12.73M -14.0% |
-$11.17M -9.7% |
-$10.19M -71.9% |
-$5.93M -146.2% |
-$2.41M | — |
| Shares Outstanding | 1.70M +273.6% |
454,169 -94.9% |
8.93M +2.2% |
8.73M +832.9% |
936,213 | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $106.6K | -96.0% | -85.1% |
| Revenue (ASC 606) | September 30, 2024 | $2.66M | -4.2% | -7.0% |
| Net Income | September 30, 2025 | -$2.78M | -93.1% | -165.5% |
| Diluted EPS | September 30, 2025 | -$0.48 | +77.1% | -14.3% |
| Total Assets | September 30, 2025 | $9.00M | -20.1% | +49.1% |
| Cash and Equivalents | September 30, 2024 | $1.75M | -35.6% | -18.6% |
| Stockholders Equity | September 30, 2025 | $3.07M | -34.8% | +394.0% |
| Operating Income | September 30, 2025 | -$2.83M | -66.0% | -55.4% |
| Shares Outstanding | September 30, 2025 | 9.77M | +1077.5% | +291.3% |
- iSpecimen Inc. reported Total Revenue of $9.29 million for fiscal year 2024.
- iSpecimen Inc. showed a decrease of -6.4% in Total Revenue compared to the prior fiscal year.
- iSpecimen Inc. reported Revenue (ASC 606) of $9.93 million for fiscal year 2023.
- iSpecimen Inc. showed a decrease of -4.6% in Revenue (ASC 606) compared to the prior fiscal year.
- iSpecimen Inc. reported Net Income of -$12.50 million for fiscal year 2024.
- iSpecimen Inc. showed a decrease of -12.6% in Net Income compared to the prior fiscal year.
- iSpecimen Inc. reported Diluted EPS of $17.58 per share (loss) for fiscal year 2024.
- iSpecimen Inc. showed an increase of +28.4% in Diluted EPS compared to the prior fiscal year.
- iSpecimen Inc. reported Total Assets of $9.35 million for fiscal year 2024.
- iSpecimen Inc. showed a decrease of -40.9% in Total Assets compared to the prior fiscal year.
- iSpecimen Inc. reported Cash and Equivalents of $1.88 million for fiscal year 2024.
- iSpecimen Inc. showed a decrease of -19.9% in Cash and Equivalents compared to the prior fiscal year.
- iSpecimen Inc. reported Stockholders Equity of $3.31 million for fiscal year 2024.
- iSpecimen Inc. showed a decrease of -66.0% in Stockholders Equity compared to the prior fiscal year.
- iSpecimen Inc. reported Operating Income of -$12.73 million for fiscal year 2024.
- iSpecimen Inc. showed a decrease of -14.0% in Operating Income compared to the prior fiscal year.
- iSpecimen Inc. reported Shares Outstanding of 1.70 million shares for fiscal year 2024.
- iSpecimen Inc. showed an increase of +273.6% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: